Companion Diagnostic Antibody for CA6 Detection
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Developing drugs for therapeutic use in patient populations is challenging due to difficulties in establishing drug interactions with intended molecular targets, determining target relevance to the disease, and identifying optimal dosing, which can be addressed by developing companion diagnostics that combine with molecular imaging for non-invasive assessment.
Innovation Solution
A companion diagnostic antibody-like binding protein based on the humanized monoclonal antibody DS6 is developed for in vivo detection and quantification of the tumor-associated MUC1-sialoglycotope CA6 using PET bio-imaging, facilitating patient stratification and early evaluation of therapeutic efficacy, and enabling identification of potential responders to the huDS6-DM4 antibody-drug immunoconjugate.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Measurement precision
If traditional drug development without companion diagnostic is used, then development cost and time are reduced, but the ability to establish drug interactions with intended molecular targets and identify optimal dosing is insufficient
Solution Approach 1:
The patent uses a companion diagnostic antibody as an intermediary tool to detect drug-target interactions. The diagnostic antibody specifically binds to the same molecular target (CA6) as the therapeutic antibody-drug conjugate, enabling non-invasive detection of target presence and drug binding in vivo through PET imaging. This intermediary diagnostic system provides precise measurement of drug-target interaction without requiring complex surgical biopsies or invasive monitoring.
2Measurement precision
If invasive methods are used to assess drug-target interaction, then measurement precision is improved, but patient safety and ease of operation deteriorate
Solution Approach 1:
The patent replaces invasive mechanical biopsy procedures with non-invasive molecular imaging (PET scan). Instead of surgically removing tissue samples to assess target expression and drug binding, the system uses radiolabeled diagnostic antibodies that circulate in the patient's bloodstream and bind to the target antigen, with signal detection performed externally via PET imaging. This substitution eliminates surgical risks while maintaining measurement precision.
3Adaptability or versatility
If companion diagnostic with molecular imaging is implemented, then patient stratification and dosing optimization are improved, but cost and device complexity increase
Solution Approach 1:
The companion diagnostic antibody is designed with multi-functionality: it serves both as a diagnostic probe for PET imaging and as a surrogate for the therapeutic antibody-drug conjugate. The same antibody variable regions recognize the target antigen in both the diagnostic and therapeutic contexts, allowing a single molecular entity to fulfill multiple roles. This universality reduces overall system complexity compared to using entirely separate diagnostic and therapeutic agents.
4Productivity
If rapid imaging with short exposure times is used, then productivity is improved, but image quality and measurement precision may deteriorate
Solution Approach 1:
The patent optimizes the diagnostic antibody's binding affinity and pharmacokinetic parameters to achieve rapid target binding and fast blood clearance. The antibody is engineered with high affinity for the CA6 antigen, enabling quick saturation of target sites. Additionally, the Fc region is modified to reduce binding to Fc receptors, accelerating renal clearance and reducing background signal. These parameter changes allow high-quality quantitative imaging within 48-24 hours or less, balancing imaging speed with measurement precision.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The companion diagnostic antibody-like binding protein allows for precise identification of patients with high CA6 expression, enabling targeted treatment with huDS6-DM4 and monitoring treatment response, thereby improving drug development and delivery to appropriate patients.
Implementation Method 1
The antibody-like binding protein can be used as a diagnostic tool for in vivo detection and quantification of the human CA6 tumor antigen by a bio-imaging technique, such as PET, wherein the antibody-like binding protein is conjugated to a suitable chelator for coupling to the bio-imaging tracer.
Implementation Method 2
A companion diagnostic antibody-like binding protein based on the humanized monoclonal antibody DS6 was developed for use as a diagnostic tool for in vivo detection and quantification of the tumor-associated MUC1-sialoglycotope, CA6
Data Source
AI summary
The invention relates to a companion diagnostic antibody-like binding protein based on the humanized monoclonal antibody, DS6, to be used as diagnostic tool for in vivo detection and quantification of the tumor-associated MUCl-sialoglycotope, CA6.